FDA Approves Trial for Intraoperative Image-Guided Cancer Surgery System
By MedImaging International staff writers Posted on 15 Jun 2015 |
The US Food and Drug Administration (FDA) has provided Investigational Device Exemption (IDE) approval for company to trial a new image-guided cancer surgery system for intraoperative imaging of breast cancer.
The surgical system consists of a cancer-specific molecular imaging agent, and a lightweight hand-held single-cell detection imaging device, and is intended for use within existing workflow of the breast cancer surgeries.
The system was developed by Lumicell (Wellesley, MA, USA), and the trial will be carried out at the Massachusetts General Hospital (MGH; Boston, MA, USA). The trial is being funded by the US National Cancer Institute (NCI) as part of the NCI Experimental Therapeutics (NExT) program.
The Lumicell surgical system addresses the need to remove all cancer cells in the tumor bed, during the first surgery. The intraoperative detection system enables surgeons to find and remove residual cancer cells, in real-time, in the tumor bed.
W. David Lee, CEO of Lumicell, said, “Launching a feasibility study for intraoperative imaging of breast cancer during surgery is a critical next step for Lumicell. The NCI grant allows our team to demonstrate the efficacy of our system in reducing rates of positive margins and repeat surgeries. By enabling surgeons to remove sub-millimeter residual cancer, we expect to improve patient outcomes.”
Related Links:
Lumicell
MGH
The surgical system consists of a cancer-specific molecular imaging agent, and a lightweight hand-held single-cell detection imaging device, and is intended for use within existing workflow of the breast cancer surgeries.
The system was developed by Lumicell (Wellesley, MA, USA), and the trial will be carried out at the Massachusetts General Hospital (MGH; Boston, MA, USA). The trial is being funded by the US National Cancer Institute (NCI) as part of the NCI Experimental Therapeutics (NExT) program.
The Lumicell surgical system addresses the need to remove all cancer cells in the tumor bed, during the first surgery. The intraoperative detection system enables surgeons to find and remove residual cancer cells, in real-time, in the tumor bed.
W. David Lee, CEO of Lumicell, said, “Launching a feasibility study for intraoperative imaging of breast cancer during surgery is a critical next step for Lumicell. The NCI grant allows our team to demonstrate the efficacy of our system in reducing rates of positive margins and repeat surgeries. By enabling surgeons to remove sub-millimeter residual cancer, we expect to improve patient outcomes.”
Related Links:
Lumicell
MGH
Latest General/Advanced Imaging News
- AI Predicts Cardiac Risk and Mortality from Routine Chest CT Scans
- Radiation Therapy Computed Tomography Solution Boosts Imaging Accuracy
- PET Scans Reveal Hidden Inflammation in Multiple Sclerosis Patients
- Artificial Intelligence Evaluates Cardiovascular Risk from CT Scans
- New AI Method Captures Uncertainty in Medical Images
- CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
- Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
- CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
- Minimally Invasive Procedure Could Help Patients Avoid Thyroid Surgery
- Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery
- AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning
- Imaging Technology Provides Ground-Breaking New Approach for Diagnosing and Treating Bowel Cancer
- CT Coronary Calcium Scoring Predicts Heart Attacks and Strokes
- AI Model Detects 90% of Lymphatic Cancer Cases from PET and CT Images
- Breakthrough Technology Revolutionizes Breast Imaging
- State-Of-The-Art System Enhances Accuracy of Image-Guided Diagnostic and Interventional Procedures